A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT04819100. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
Study identification
- NCT ID
- NCT04819100
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2021 (Actual)
- Primary completion
- Jan 12, 2026 (Actual)
- Completion
- May 2028 (Estimated)
- Last update posted
- Mar 4, 2026
2021 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology - Santa Monica | Los Angeles | California | 90404 | — |
| Stockton Hematology Oncology Group | Stockton | California | 95204 | — |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | 90502 | — |
| GenesisCare | Aventura | Florida | 33180 | — |
| GenesisCare - Boca Raton | Boca Raton | Florida | 33431 | — |
| USO-Cancer Care Center of Brevard, Inc. | Palm Bay | Florida | 32909 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | 55905 | — |
| USO-New York Oncology Hematology, P.C | Latham | New York | 12110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| USO - Alliance Cancer Specialists, PC | Horsham | Pennsylvania | 19044 | — |
| Sarah Cannon Research Institute SCRI | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology Nashville | Nashville | Tennessee | 37203 | — |
| USO-Texas Oncology-Central/South Texas | Austin | Texas | 78705 | — |
| US Oncology | The Woodlands | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 196 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04819100, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04819100 live on ClinicalTrials.gov.